KKR closed an all-cash acquisition of Integer Holdings for $5.7 billion, removing one of the largest contract development and manufacturing organizations in medical devices from public markets. The transaction adds a diversified production platform—cardiac rhythm management, neuromodulation, surgical devices—to KKR's healthcare portfolio at a moment when device OEMs are increasingly outsourcing complex manufacturing to de-risk supply chains.
Integer operates 40 manufacturing sites across 10 countries and generates revenue from both component supply and full-product manufacturing for companies like Medtronic, Boston Scientific, and Abbott. The company reported $1.4 billion in trailing twelve-month revenue as of its last public filing, with operating margins near 14% and a customer concentration that has historically worried public equity holders but appeals to private capital seeking sticky, infrastructure-like cash flows. KKR did not disclose financing details, though the firm has deployed over $20 billion into healthcare since 2020 and maintains a dedicated medtech fund.
The deal matters because it removes capacity optionality from the public market at a time when onshoring and regulatory pressure are forcing device companies to rethink manufacturing footprints. Integer's scale—particularly in cardiac implantables and neuromodulation—positions it as critical infrastructure for OEMs that cannot afford to build or maintain comparable capabilities in-house. KKR's ownership likely accelerates consolidation within the CDMO space, either through bolt-on acquisitions or by leaning into contract structures that lock in long-term volume commitments in exchange for capex co-investment. The firm has form here: its 2021 acquisition of Nephron Pharmaceuticals and ongoing build-out of Envision Healthcare suggest KKR views scaled, asset-heavy medical infrastructure as a hedge against volatility in traditional growth equity.
For allocators, the immediate question is whether KKR refinances Integer's existing $1.1 billion debt load or uses the balance sheet to fund expansion into higher-margin product categories like robotics components or advanced surgical tools. The company's gross margins have hovered near 24%, compressed by mix shift toward lower-margin cardiac work, and KKR will need to either improve throughput or shift the customer mix toward higher-value contracts. The private structure also removes quarterly earnings pressure that had constrained Integer's ability to make long-cycle investments in automation and advanced manufacturing, which typically require 18-24 months to generate returns.
Watch for two things over the next six months: first, whether KKR installs a new management team with experience scaling CDMO platforms under private ownership, and second, whether the firm begins soliciting bolt-on targets in adjacent verticals like microelectronics for implantables or polymer-based surgical consumables. Integer's public filings showed 23% of revenue coming from neuromodulation, a category growing at double the rate of cardiac, and any signal that KKR is reallocating capex toward that segment would suggest a tilt toward growth rather than yield optimization.
The transaction closed without regulatory objection, and Integer's last traded price was $127.50 per share, implying KKR paid a premium near 32% to the 90-day volume-weighted average. That premium, in a market where medtech multiples have compressed 18% year-over-year, suggests KKR sees structural upside in manufacturing scale that public markets no longer price accurately.